Analysts show less optimism post-results due to lowered reve...

Analysts show less optimism post-results due to lowered revenue forecasts and minor EPS downgrade. Despite growth acceleration, China Resources Double-Crane PharmaceuticalLtd is predicted to lag behind industry average. Concerns arise as EPS estimates are reduced, indicating potential business challenges.